×
Workplace flexibility significantly impacts employment for patients with RA
https://www.healio.com/rheumatology/rheumatoid-arthritis/news/online/%7B21372e0e-c397-4c8a-8a9d-0541963b3956%7D/workplace-flexibility-significantly-impacts-employment-for-patients-with-ra

Nov 9th, 2018 - Less flexible work arrangements and more physically demanding jobs were linked to a higher unemployment rate among patients with rheumatoid arthritis, according to data presented at the ACR/ARHP 2018 Annual Meeting.

AVERT-2 fails to meet primary endpoint, but data advances the field for RA
https://www.healio.com/rheumatology/rheumatoid-arthritis/news/online/%7B5fe7c1bb-81f5-48a0-b039-c418a616a55d%7D/avert-2-fails-to-meet-primary-endpoint-but-data-advances-the-field-for-ra

Nov 6th, 2018 - Although the AVERT-2 study failed to meet the primary endpoint of a statistically significant difference in SDAI ≤3.3 at 24 weeks, Sheila Kelly, MD, the medical team lead for immunoscience at Bristol-Myers Squibb, sat down with Healio Rheumatology to discuss how the results have nevertheless provided new insight into treatment with abatacept in patients with newly diagnosed ACPA-positive rheuma...

Half of patients with RA do not modify therapies to meet treat-to-target guidelines
https://www.healio.com/rheumatology/rheumatoid-arthritis/news/online/%7B74c5d0ed-964e-4832-8708-a53404564028%7D/baricitinib-maintains-safety-profile-in-ra-shows-promise-for-lupus

Oct 31st, 2018 - Terence Rooney, MD, senior medical director for Eli Lilly, highlights recent findings from an updated integrated safety analysis of baricitinib from a long-term study of patients with rheumatoid arthritis treated up to six years.